Related Experiment Video
Updated: Nov 21, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
A paraneoplastic syndrome exacerbated by checkpoint inhibition therapy
Heather Villarreal1, Kathryn H Dao2
1Department of Internal Medicine, Baylor Scott and White Medical Center - Temple, Texas.
Abstract:
Polymyalgia rheumatica is a disease characterized by systemic inflammation of the proximal muscles and pain in the hips and shoulders, but when this disease occurs contemporaneously with malignancy, there is a possibility of it being a paraneoplastic syndrome. With the advent of immunotherapies to treat various cancers, immune-related adverse events from these therapies are recognized as de novo findings or as flares of an underlying existing rheumatic disease. In this report, we present a case of polymyalgia rheumatica presenting as a paraneoplastic syndrome that was exacerbated during therapy with immune checkpoint inhibitors for recurrent melanoma.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

